Entresto (sacubitril and valsartan) is prescribed to treat certain types of heart failure. The drug comes as tablets to swallow and capsules to open and sprinkle on food. You usually take it twice ...

If you’re looking at treatment options for heart failure, you may want to learn more about Entresto (sacubitril/valsartan). It’s a prescription drug used to treat ...

Entresto (sacubitril/valsartan) is a brand-name prescription medication and is approved it to treat certain types of heart failure in adults. Additionally, Entresto ...

Heart failure patients unable to reach the target dose of angiotensin receptor/neprilysin inhibitor (ARNI) therapy still reaped gains in health status a year later, according to a post hoc analysis of ...

Entresto (sacubitril/valsartan) is a brand-name drug prescribed to treat heart failure. Entresto has interactions with some other drugs and certain supplements ...

Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...

Entresto, Novartis's novel heart failure (HF) drug, gained FDA approval earlier today. The approval arrived six weeks ahead of the drug's action date. Formerly known as LCZ 696, the drug had already ...

Novartis' heart failure drug Entresto has been on the ascent after a slower-than-expected debut on the market, and now the drug has an expanded FDA label that could widen its reach to millions of new ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and Drug Administration (FDA) has approved the first generics of Entresto ® ...

Novartis is banking on a broader label to expand the reach of its blockbuster heart med Entresto, but in patients who've suffered prior heart attacks, the drug just hit a setback. In the phase 3 ...